bluebird bio: Tender Offer Extended to April 18, 2025
Deal News | Apr 03, 2025 | SK Capital
Carlyle and SK Capital Partners have announced the extension of their tender offer to acquire all outstanding shares of bluebird bio, a leader in gene therapy, until April 18, 2025. The offer, initially set to expire on April 4, 2025, was extended to allow more time for satisfying certain conditions such as regulatory approvals and the tendering of a majority of bluebird's shares. As of April 2, 2025, approximately 65,120 shares had been tendered. This move aligns with SK Capital's focus on transforming businesses in the life sciences sector and Carlyle's strategy to invest wisely. Documents detailing the offer conditions were filed with the SEC, and bluebird has responded with a Solicitation/Recommendation Statement. Bluebird bio is notable for pioneering ex-vivo gene therapy solutions for diseases like sickle cell and cerebral adrenoleukodystrophy. Carlyle and SK Capital aim to build and transform sustainable businesses within their portfolio.
Sectors
- Life Sciences
- Private Equity
Geography
- United States – bluebird bio and the acquiring entities Carlyle and SK Capital are based in the United States, and the acquisition involves U.S. regulatory processes.
Industry
- Life Sciences – bluebird bio operates in the life sciences sector, focusing on gene therapy for severe genetic diseases.
- Private Equity – SK Capital and Carlyle are private equity firms involved in the acquisition of bluebird bio.
Financials
- $441 billion – Carlyle's assets under management as of December 31, 2024.
- $9 billion – SK Capital's assets under management.
- $12 billion – Annual revenue generated by SK Capital's portfolio of businesses.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| bluebird bio, Inc. | Target Company | Company | A leading company in gene therapy, known for developing treatments for severe genetic diseases. |
| Carlyle Group | Bidding Company | Company | A global private equity firm involved in the tender offer for bluebird bio. |
| SK Capital Partners | Bidding Company | Company | A private investment firm focused on the life sciences sector, collaborating with Carlyle in the bluebird bio acquisition. |
| Beacon Parent Holdings, L.P. | Bidding Company | Company | The parent company involved in the offer to purchase bluebird bio's shares. |
| Beacon Merger Sub, Inc. | Bidding Company | Company | A subsidiary created for the purpose of merging with bluebird bio in the acquisition process. |
| Equiniti Trust Company, LLC | Depositary Agent | Company | The company serving as the depositary for the tender offer. |